AAP
MCRB icon

Arax Advisory Partners’s Seres Therapeutics MCRB Stock Holding History

Arax Advisory Partners’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18 Buy
6
+4
+200% +$47 ﹤0.01% 3723
2025
Q4 		$30 Hold
2
– – ﹤0.01% 3994
2025
Q3 		$38 Buy
+2
New +$32 ﹤0.01% 3545

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $31.4B AUM 31.97% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Arax Advisory Partners's MCRB Position: Q1 2026 in Review

Arax Advisory Partners increased its Seres Therapeutics (MCRB) stake by 200% in Q1 2026, buying an estimated $47 and bringing the position to 6 shares worth $18. The position accounts for ﹤0.01% of the portfolio, ranked #3723.

Arax Advisory Partners first reported a position in MCRB in Q3 2025 and has held it in 3 quarters since. The position peaked at $38 in Q3 2025. 33 funds tracked by Wall St. Rank hold MCRB as of Q1 2026.

  • Arax Advisory Partners held 6 shares of Seres Therapeutics worth $18 as of Q1 2026.
  • Arax Advisory Partners bought 4 Seres Therapeutics shares in Q1 2026, an estimated $47.
  • Seres Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #3723 holding.
  • Arax Advisory Partners first reported a position in Seres Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Arax Advisory Partners's Seres Therapeutics position peaked at $38 in Q3 2025.
  • 33 funds tracked by Wall St. Rank held Seres Therapeutics as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.